Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Francois,Gonzalvez ^[1] ; Sylvie,Vincent ^[2] ; Theresa E,Baker ^[1] ; Alexandra E,Gould ^[2] ; Shuai,Li ^[3] ; Scott D,Wardwell ^[1] ; Sara,Nadworny ^[1] ; Yaoyu,Ning ^[1] ; Sen,Zhang ^[1] ; Wei-Sheng,Huang ^[1] ; Yongbo,Hu ^[2] ; Feng,Li ^[1] ; Matthew T,Greenfield ^[1] ; Stephan G,Zech ^[1] ; Biplab,Das ^[1] ; Narayana I,Narasimhan ^[1] ; Tim,Clackson ^[1] ; David,Dalgarno ^[1] ; William C,Shakespeare ^[1] ; Michael,Fitzgerald ^[2] ; Johara,Chouitar ^[2] ; Robert J,Griffin ^[2] ; Shengwu,Liu ^[4] ; Kwok-Kin,Wong ^[3] ; Xiaotian,Zhu ^[1] ; Victor M,Rivera ^[5]

作者单位： ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. ^[1] Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. ^[2] Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, NYU Langone Health, New York, New York. ^[3] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. ^[4] ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Victor.Rivera@TheseusPharma.com. ^[5]